The estimated Net Worth of R Paul Gray is at least 2.6 百万$ dollars as of 1 November 2013. Kevin Gray owns over 7,500 units of United Therapeutics Corp stock worth over 2,596,425$ and over the last 20 years he sold UTHR stock worth over 0$.
Kevin has made over 33 trades of the United Therapeutics Corp stock since 2005, according to the Form 4 filled with the SEC. Most recently he exercised 7,500 units of UTHR stock worth 360,825$ on 1 November 2013.
The largest trade he's ever made was exercising 66,000 units of United Therapeutics Corp stock on 3 May 2011 worth over 2,346,960$. On average, Kevin trades about 3,978 units every 67 days since 2005. As of 1 November 2013 he still owns at least 7,500 units of United Therapeutics Corp stock.
You can see the complete history of Kevin Gray stock trades at the bottom of the page.
Kevin T. Gray is the Sr. VP of Strategic Operations & Logistics at United Therapeutics Corp.
R's mailing address filed with the SEC is C/O UNITED THERAPEUTICS CORP, 1110 SPRING STREET, SILVER SPRINGS, MD, 20910.
Over the last 20 years, insiders at United Therapeutics Corp have traded over 68,910,395$ worth of United Therapeutics Corp stock and bought 229,703 units worth 13,655,671$ . The most active insiders traders include Martine A Rothblatt、David Zaccardelli、Roger Jeffs. On average, United Therapeutics Corp executives and independent directors trade stock every 3 days with the average trade being worth of 2,310,818$. The most recent stock trade was executed by James Edgemond on 9 September 2024, trading 8,332 units of UTHR stock currently worth 991,341$.
united therapeutics corporation is a biotechnology company focused on the development and commercialization of unique products to address the unmet medical needs of patients with chronic and life-threatening conditions. we currently have five approved products on the market, and a long-term mission of providing an unlimited supply of transplantable organs for those who need them! our employees can be found collaborating across the united states, europe and asia. as a group, we are relentless in our pursuit of “medicines for life” and continue to research and develop treatments for cardiovascular and pulmonary diseases, pediatric cancers, and other orphan diseases. #weareunitherians
United Therapeutics Corp executives and other stock owners filed with the SEC include: